Rising, 2mg/5 mL recall — Rising Pharma Holding, Inc. (Class II)

Rising Pharma Holding, Inc. is recorded by the U.S. Food and Drug Administration (FDA) as recalling Rising, 2mg/5 mL — a Class II recall, initiated 2026-07-13 and posted to the FDA enforcement report on 2026-07-29, under recall number D-0724-2026. Status Ongoing, with no termination date on the record. The reason the FDA record carries is, verbatim: “Presence of Precipitate: medication was crystallizing and particles floating in the bottle”. From the product description, the form is syrup, the strengths given are 2mg/5 mL and 473 mL and it is marked Rx only. 1 National Drug Code number is printed in the record: 64980-504-48. Distribution is recorded as “Nationwide U.S.A” — Nationwide (US), with the recalling firm on record in NJ, United States. It is the only recall number the FDA has filed under event ID 99401. Values are reproduced from the linked openFDA report; regulatory information, not medical advice.

Regulatory snapshot

Recall number D-0724-2026
FDA event ID 99401
Classification Class II (intermediate regulatory tier)
Status Ongoing
Recalling firm Rising Pharma Holding, Inc.
Recall initiated 2026-07-13
Reported by FDA 2026-07-29
Report lag 16 days from initiation to report
Distribution Nationwide U.S.A. — Nationwide (US)
Firm location on record NJ, United States
Product description (source) Rising, Cyproheptadine Hydrochloride Syrup, 2mg/5 mL, 473 mL (ONE PINT), Rx only, Manufactured for: Rising Pharma Holdings, Inc., East Brunswick, NJ, Manufactured by: Lyne Laboratories, Inc., Brockton, MA. NDC 64980-504-48.

Reason reported by FDA

Presence of Precipitate: medication was crystallizing and particles floating in the bottle

12 words from the enforcement report field reason_for_recall, reproduced without edit — the firm's own wording, not an assessment.

Product identifiers in this record

7 identifying values matched by exact pattern in the 30-word product description above; each is a literal substring of it.

Product named Rising
Form Syrup
Strength 2mg/5 mL · 473 mL
NDC 64980-504-48
Marketing category Rx only
Manufactured by Lyne Laboratories, Inc.
Manufactured for Rising Pharma Holdings, Inc.

Reported in the same month (2026-07)

111 enforcement reports carry a report date in 2026-07; these 8 are the Class II ones nearest this record.

Recall recordRecall numberRecalling firmFDA tierReported
Levothyroxine Sodium Tablets, 25 mcgD-0700-2026Major PharmaceuticalsClass II2026-07-29
Levothyroxine Sodium Tablets, 50 mcgD-0701-2026Major PharmaceuticalsClass II2026-07-29
Levothyroxine Sodium Tablets, 75 mcgD-0702-2026Major PharmaceuticalsClass II2026-07-29
Levothyroxine Sodium Tablets, 88 mcgD-0703-2026Major PharmaceuticalsClass II2026-07-29
Levothyroxine Sodium Tablets, 112 mcgD-0704-2026Major PharmaceuticalsClass II2026-07-29
Levothyroxine Sodium Tablets, 125 mcgD-0705-2026Major PharmaceuticalsClass II2026-07-29
Levothyroxine Sodium Tablets, 150 mcgD-0706-2026Major PharmaceuticalsClass II2026-07-29
Levothyroxine Sodium Tablets, 25 mcgD-0707-2026Major PharmaceuticalsClass II2026-07-29

Nearest Class II recalls by date

213 of 250 indexed records share the Class II tier; the 8 nearest to 2026-07-29 by report date are listed here.

Recall recordRecall numberRecalling firmStrength / formReported
Levothyroxine Sodium Tablets, 50 mcgD-0708-2026Major Pharmaceuticals50 mcg · Tablets2026-07-29
Levothyroxine Sodium Tablets, 75 mcgD-0709-2026Major Pharmaceuticals75 mcg · Tablets2026-07-29
Levothyroxine Sodium Tablets, 125 mcgD-0710-2026Major Pharmaceuticals125 mcg · Tablets2026-07-29
Levothyroxine Sodium Tablets, 150 mcgD-0711-2026Major Pharmaceuticals150 mcg · Tablets2026-07-29
Amlodipine and Olmesartan Medoxomil Tablets, 10 mg/20 mgD-0712-2026Ascend Laboratories, LLC10 mg/20 mg · Tablets2026-07-29
Rohto Cooling Eye Drops ALL-IN-ONE, 0.2%D-0715-2026Rohto-mentholatum (vietnam) Co., Ltd.0.2% · Eye Drops2026-07-29
Rohto Cooling Eye Drops Max Strength, 0.03%D-0716-2026Rohto-mentholatum (vietnam) Co., Ltd.0.03% · Eye Drops2026-07-29
Rohto Cooling Eye Drops Max Strength, 0.03%D-0717-2026Rohto-mentholatum (vietnam) Co., Ltd.0.03% · Eye Drops2026-07-29

Reading this record

Class II is the FDA's own severity tier for the recall action — 213 of the 250 indexed records carry it — and it describes the agency's assessment of the action, not a risk statement about any individual. Match a package against 64980-504-48 at the FDA source to confirm it is covered.

Namespace context: the Class II index (213 records) and the recall hub (250 records, 118 FDA events); Rising Pharma Holding, Inc. (1 indexed records) aggregates this firm across datasets.

Coverage and limits of this record

This page reflects the openFDA enforcement report for D-0724-2026 as ingested on 2026-08-22, which can lag the live FDA record and omits detail held only in primary documents. It offers no clinical assessment, no advice about whether to use any product, and no substitute. For any health question consult a qualified healthcare professional.

Source & provenance

Official source
https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0724-2026%22
Source dataset
openFDA Drug Enforcement API
Publication date
2026-07-29
Ingested
2026-08-22
Record hash
e9036df52f9b6238

Verify every value against the official FDA source above. This site links to the regulator's record rather than replacing it.